Page 1 of 2
`
`<DOCUMENT>
`<TYPE>EX-99
`<SEQUENCE>2
`<FILENAME>exhibit991.txt
`<DESCRIPTION>PRESS RELEASE
`<TEXT>
` Exhibit 99.1
` ------------
`
`RELEASE: IMMEDIATE Investor Contact: Bernard Patriacca - VP/CFO
` (781) 862-4003
`
` MACROCHEM DISCONTINUES RESEARCH AND PRODUCT DEVELOPMENT ACTIVITIES, TERMINATES
` SUBSTANTIALLY ALL NON-MANAGEMENT PERSONNEL, WILL SEEK
` BUYER FOR COMPANY OR ITS ASSETS
` SEPTEMBER 1, 2005, LEXINGTON, MA - At the direction of its board of
`directors, MacroChem Corporation (Nasdaq: MCHM) is discontinuing all research
`and product development activities. The Company will seek to sell the business
`or its assets. As previously announced, the Company has been evaluating
`strategic alternatives, such as raising additional capital or a merger or
`acquisition, a sale of the Company or a sale or licensing of its intellectual
`property. To date, the Company has been unable to identify a satisfactory
`strategic alternative.
` On August 31, 2005, the Company terminated substantially all its
`non-management personnel. The Company expects to incur a charge of approximately
`$350,000 in the quarter ending September 30, 2005 in connection with these
`terminations and the discontinuation of research and product development
`activities. The Company is currently discussing with its executive officers the
`restructuring of the Company's contractual obligations to those officers to
`reduce expenses.
` The Company intends to attempt to sell the business or its intellectual
`property and other operating assets as soon as possible. There is no assurance
`that these efforts will be successful or that there will be any assets remaining
`to be distributed to stockholders. The Company believes that it has sufficient
`resources to fund expenses for the next three months in connection with its
`efforts to sell the business or its assets, and has entered into a three month
`sublease of a limited amount of office space at its current address for this
`purpose.
` In addition to its portfolio of intellectual property and early-stage
`product candidates, MacroChem has two clinical-stage product candidates
`containing its patented enhancer, SEPA(R): Opterone(R), a topical cream for male
`testosterone deficiency, and EcoNail(TM), a SEPA-enhanced antifungal nail
`lacquer to treat a common and potentially debilitating nail infection known as
`onychomycosis.
`FORWARD-LOOKING STATEMENTS
` WITH THE EXCEPTION OF HISTORICAL INFORMATION CONTAINED IN THIS PRESS
`RELEASE, THE MATTERS DESCRIBED HEREIN ARE FORWARD-LOOKING STATEMENTS THAT
`INVOLVE RISKS AND UNCERTAINTIES. MACROCHEM'S ACTUAL RESULTS MAY DIFFER
`SIGNIFICANTLY FROM THE RESULTS DISCUSSED IN THE FORWARD-LOOKING STATEMENTS.
`
`http://www.sec.gov/Archives/edgar/data/743884/000074388405000054/exhibit991.txt
`
`5/24/2016
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2177 - 1/2
`
`

`
`Page 2 of 2
`
`FACTORS THAT MIGHT CAUSE SUCH A DIFFERENCE INCLUDE, BUT ARE NOT LIMITED TO,
`THOSE DISCUSSED OR REFERRED TO IN THE SECTION ENTITLED "RISK FACTORS" IN
`MACROCHEM'S ANNUAL REPORT ON FORM 10-K, AS WELL AS THOSE DISCUSSED ELSEWHERE
`THEREIN, AND INCLUDE, WITHOUT LIMITATION, RISKS REGARDING PRODUCT DEVELOPMENT,
`THE TIMING AND RESULTS OF CLINICAL TRIALS, THE REGULATORY APPROVAL PROCESS,
`CAPITAL REQUIREMENTS, FINANCIAL CONDITION, PATENT PROTECTION AND DEPENDENCE ON
`THIRD PARTIES FOR DEVELOPMENT AND LICENSING ARRANGEMENTS. READERS ARE CAUTIONED
`NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK
`ONLY AS OF THE DATE HEREOF. MACROCHEM UNDERTAKES NO OBLIGATION TO UPDATE
`PUBLICLY ANY FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION,
`FUTURE EVENTS OR OTHERWISE. FOR MORE INFORMATION VISIT OUR WEBSITE,
`HTTP://WWW.MACROCHEM.COM.
` # # #
`</TEXT>
`</DOCUMENT>
`
`http://www.sec.gov/Archives/edgar/data/743884/000074388405000054/exhibit991.txt
`
`5/24/2016
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2177 - 2/2